Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis

Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of anticitrullinated protein antibodies in the last century ha...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of Inflammation 2014-01, Vol.2014 (5), p.75-93
Main Authors: Ponchel, Frédérique, Emery, Paul, Nissim, Ahuva, Vital, Ed, Ryan, Brent J., Strollo, Rocky, Boissinot, Marjorie, Hunt, Laura, Burska, Agata N., Winyard, Paul G.
Format: Article
Language:English
Subjects:
Animals
Antigens - chemistry
Antioxidants - chemistry
Arthritis
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - metabolism
Autoantibodies - immunology
Autoimmunity
B-Lymphocytes - cytology
Biomarkers - metabolism
Citrulline - chemistry
Humans
Inflammation - metabolism
Oxygen - chemistry
Protein Processing, Post-Translational
Proteins
Reactive Oxygen Species - metabolism
Review
Rheumatoid factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs). Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of anticitrullinated protein antibodies in the last century has changed this and other posttranslational modifications (PTM) relevant to RA have since been described. Such PTM introduce neoepitopes in proteins that can generate novel autoantibody specificities. The recent recognition of these novel specificities in RA provides a unique opportunity to understand human B-cell development in vivo. In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation, and oxidation. With the advancement of research methodologies it should be expected that other autoantibodies against PTM proteins could be discovered in patients with autoimmune diseases. Many of such autoantibodies may provide significant biomarker potential.
ISSN:0962-9351
1466-1861
DOI:10.1155/2014/492873